publication date: Mar. 30, 2018

CTEP Protocols

NCI Trials for March

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I/11 – 10107

Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Mayo Clinic Cancer Center LAO

Mansfield, Aaron S.

(507) 293-0569


Phase II – EA5152

A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC

ECOG-ACRIN Cancer Research Group

Neal, Joel William

(650) 725-3081


Phase III – AGCT1532

A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors

Children’s Oncology Group

Pashankar, Farzana

(203) 785-7344


Phase Other – ANBL17B4-Q

Serial Sequencing of Neuroblastoma

Children’s Oncology Group

Roberts, Stephen S.

(212) 639-4034

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.